Home
ARCT
ARCT News

Latest Arcturus Therapeutics Holdings Inc. (ARCT) News on January 19, 2025

Arcturus Therapeutics launches Phase I Avian Influenza trials in US

Clinical Trials Arena

9 days ago

Arcturus Therapeutics launches Phase I Avian Influenza trials in US

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

Business Wire

9 days ago

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

MT Newswires

13 days ago

Arcturus Starts Dosing in Phase 2 Cystic Fibrosis, Ornithine Transcarbamylase Deficiency Treatment Studies

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Business Wire

13 days ago

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

High Growth Tech Stocks Including Arcturus Therapeutics Holdings And Two Others

Simply Wall St.

a month ago

High Growth Tech Stocks Including Arcturus Therapeutics Holdings And Two Others

We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate

Simply Wall St.

a month ago

We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire

a month ago

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers

Insider Monkey

a month ago

Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Business Wire

2 months ago

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Business Wire

2 months ago

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Business Wire

2 months ago

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

MT Newswires

2 months ago

Arcturus Therapeutics Gets FDA Greenlight for H5N1 Pandemic Flu Vaccine Trial

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Business Wire

2 months ago

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

2 months ago

Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations

Thomson Reuters StreetEvents

2 months ago

Q3 2024 Arcturus Therapeutics Holdings Inc Earnings Call

Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ...

GuruFocus.com

2 months ago

Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ...

Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates

Zacks

2 months ago

Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates

Associated Press Finance

2 months ago

Arcturus Therapeutics: Q3 Earnings Snapshot

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Business Wire

2 months ago

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Report Preview: What To Look For

GuruFocus.com

2 months ago

Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Report Preview: What To Look For

Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect

Zacks

2 months ago

Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Business Wire

3 months ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

3 months ago

Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock?

Investing in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gain

Simply Wall St.

3 months ago

Investing in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gain

A slow start for self-amplifying mRNA vaccines

Pharmaceutical Technology

3 months ago

A slow start for self-amplifying mRNA vaccines

ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty

Zacks

4 months ago

ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses

Benzinga

4 months ago

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Business Wire

4 months ago

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Here's Why Investors Should Invest in Arcturus Stock Now

Zacks

4 months ago

Here's Why Investors Should Invest in Arcturus Stock Now

MT Newswires

4 months ago

Arcturus Therapeutics, CSL's Updated Covid-19 Vaccine Approved in Japan

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

PR Newswire

4 months ago

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

New Strong Buy Stocks for September 13th

Zacks

4 months ago

New Strong Buy Stocks for September 13th

Top High Growth Tech Stocks to Watch in September 2024

Simply Wall St.

4 months ago

Top High Growth Tech Stocks to Watch in September 2024

Arcturus Therapeutics Holdings Inc. (ARCT): Among the Worst ARK Stocks According to Short Sellers

Insider Monkey

4 months ago

Arcturus Therapeutics Holdings Inc. (ARCT): Among the Worst ARK Stocks According to Short Sellers

BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years

Zacks

4 months ago

BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Business Wire

5 months ago

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect?

Zacks

5 months ago

Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect?

SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others

Zacks

5 months ago

SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Business Wire

5 months ago

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids

Zacks

5 months ago

Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids

AstraZeneca (AZN) Denies Rumors About UK Facility Relocation

Zacks

5 months ago

AstraZeneca (AZN) Denies Rumors About UK Facility Relocation

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

Zacks

5 months ago

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa

Zacks

5 months ago

J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa

What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock

Zacks

5 months ago

What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study

Zacks

5 months ago

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study

Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday

Zacks

5 months ago

Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday

Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review

Zacks

5 months ago

Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review

Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug

Zacks

5 months ago

Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug

Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe

Zacks

5 months ago

Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe

J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy

Zacks

5 months ago

J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy

Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia

Zacks

5 months ago

Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia

AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use

Zacks

5 months ago

AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

Zacks

5 months ago

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer

Zacks

5 months ago

FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer

MT Newswires

5 months ago

Leerink Partners Initiates Arcturus Therapeutics Holdings at Outperform With $70 Price Target

Arcturus Therapeutics Holdings Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Arcturus Therapeutics Holdings Second Quarter 2024 Earnings: Beats Expectations

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

Zacks

5 months ago

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

Associated Press Finance

5 months ago

Arcturus Therapeutics: Q2 Earnings Snapshot

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

Business Wire

6 months ago

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

Business Wire

6 months ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

MT Newswires

7 months ago

Arcturus Therapeutics Updates Ornithine Transcarbamylase Deficiency, Cystic Fibrosis Programs

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Business Wire

7 months ago

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Business Wire

7 months ago

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Argus Research

7 months ago

Daily – Vickers Top Buyers & Sellers for 06/17/2024

Insider Sale: CFO Andy Sassine Sells 50,000 Shares of Arcturus Therapeutics Holdings Inc (ARCT)

GuruFocus.com

7 months ago

Insider Sale: CFO Andy Sassine Sells 50,000 Shares of Arcturus Therapeutics Holdings Inc (ARCT)

MT Newswires

7 months ago

Arcturus Therapeutics Holdings Insider Sold Shares Worth $1,601,500, According to a Recent SEC Filing

MT Newswires

7 months ago

Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

Business Wire

7 months ago

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

Insider Sale: Chief Scientific Officer & COO Pad Chivukula Sells 26,000 Shares of Arcturus ...

GuruFocus.com

7 months ago

Insider Sale: Chief Scientific Officer & COO Pad Chivukula Sells 26,000 Shares of Arcturus ...

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

Business Wire

8 months ago

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

MT Newswires

8 months ago

Achilles Therapeutics Collaborating With Arcturus Therapeutics to Evaluate mRNA Personalized Cancer Vaccines

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

GlobeNewswire

8 months ago

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

PR Newswire

8 months ago

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Business Wire

8 months ago

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call Transcript

Insider Monkey

8 months ago

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call Transcript

Arcturus Therapeutics Holdings First Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

8 months ago

Arcturus Therapeutics Holdings First Quarter 2024 Earnings: Beats Expectations

GuruFocus.com

8 months ago

Arcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights: ...

Associated Press Finance

8 months ago

Arcturus Therapeutics: Q1 Earnings Snapshot

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

Business Wire

8 months ago

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

9 months ago

Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for

Zacks

9 months ago

Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for

Arcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their impressive 284% return over the last five years

Simply Wall St.

9 months ago

Arcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their impressive 284% return over the last five years

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

Business Wire

9 months ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

Arcturus Therapeutics Holdings Inc (ARCT) Insider Sells Shares

GuruFocus.com

10 months ago

Arcturus Therapeutics Holdings Inc (ARCT) Insider Sells Shares

Arcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ...

GuruFocus.com

10 months ago

Arcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ...

Arcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

10 months ago

Arcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds

Insider Monkey

10 months ago

12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript

Insider Monkey

10 months ago

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

10 months ago

Q4 2023 Arcturus Therapeutics Holdings Inc Earnings Call

Arcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline Developments

GuruFocus.com

10 months ago

Arcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline Developments

Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates

Zacks

10 months ago

Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates

Associated Press Finance

10 months ago

Arcturus Therapeutics: Q4 Earnings Snapshot

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

Business Wire

10 months ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why

Zacks

a year ago

Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff

InvestorPlace

a year ago

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff

Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

Business Wire

a year ago

Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis

Business Wire

a year ago

Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024

InvestorPlace

a year ago

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024

3 Tech Stocks That Could Be Multibaggers in the Making: February Edition

InvestorPlace

a year ago

3 Tech Stocks That Could Be Multibaggers in the Making: February Edition

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024

Business Wire

a year ago

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024

Share on Social Networks: